Nolato AB/Skr NOLA B
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Nolato AB
- Ticker
- Skr NOLA B
- Sector
- Industrials
- Primary listing
- XSTO
- Employees
- 5,692
- Headquarters
- Torekov, Sweden
- Website
- www.nolato.com
Nolato AB Metrics
BasicAdvanced
kr 14B
20.81
kr 2.50
-
kr 1.70
3.27%
Price and volume
Market cap
kr 14B
52-week high
kr 64.10
52-week low
kr 44.80
Average daily volume
230K
Dividend rate
kr 1.70
Financial strength
Current ratio
1.375
Quick ratio
0.78
Long term debt to equity
0.256
Total debt to equity
0.256
Dividend payout ratio (TTM)
60.03%
Interest coverage (TTM)
14.30%
Profitability
EBITDA (TTM)
1,475
Gross margin (TTM)
18.19%
Net profit margin (TTM)
7.02%
Operating margin (TTM)
10.00%
Effective tax rate (TTM)
24.04%
Revenue per employee (TTM)
kr 1,680,000
Management effectiveness
Return on assets (TTM)
5.84%
Return on equity (TTM)
11.77%
Valuation
Price to earnings (TTM)
20.814
Price to revenue (TTM)
1.462
Price to book
2.35
Price to tangible book (TTM)
4.37
Price to free cash flow (TTM)
38.377
Free cash flow yield (TTM)
2.61%
Free cash flow per share (TTM)
1.355
Dividend yield (TTM)
3.27%
Forward dividend yield
3.27%
Growth
Revenue change (TTM)
0.11%
Earnings per share change (TTM)
-14.44%
3-year revenue growth (CAGR)
-0.26%
10-year revenue growth (CAGR)
8.13%
3-year earnings per share growth (CAGR)
9.97%
10-year earnings per share growth (CAGR)
6.88%
3-year dividend per share growth (CAGR)
-3.64%
10-year dividend per share growth (CAGR)
5.45%
What the Analysts think about Nolato AB
Analyst ratings (Buy, Hold, Sell) for Nolato AB stock.
Analyst projections of the future price of Nolato AB stock.
Bulls say / Bears say
Medical Solutions grew 9% organically in Q3, led by higher volumes in newer drug-delivery products and in vitro diagnostics. EBITA also rose to SEK 166 million from SEK 159 million. (Investegate)
Unitron and M&M Qualtech add around SEK 600 million in annual sales at margins in line with Nolato’s, while extending its capabilities in electronics-intensive medical technology and complete product manufacturing. (Investegate, Nolato)
Profitability has weakened despite higher sales: Q3 EBITA fell to SEK 254 million from SEK 281 million and the margin dropped to 10.2% from 12.0%. For the first nine months, earnings per share also fell to SEK 1.94 from SEK 2.32. (Investegate)
Engineered Solutions remains a weak spot, with organic sales down 3% in Q3 and EBITA falling to SEK 112 million from SEK 120 million. Automotive demand fell sharply, while Hygiene continued to face inventory adjustments and lower sales. (Investegate)
Higher input costs and the time lag before Nolato can pass them on are weighing on margins, while start-up costs on new medical projects are expected to persist for several quarters. This could delay a recovery in profitability even as sales grow. (Investing.com, Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Nolato AB Financial Performance
Revenues and expenses
Nolato AB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Nolato AB
Fund name | Fund size | Skr NOLA B weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.07% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.07% |
L&G Global Quality Dividends£LDGG | $353M | 0.02% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.